surpass cvot tirzepatide results Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial In patients with type 2

SKU: 60890608295

Pay in 4 interest-free payments of $5.67 Learn more

Live Spec

In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS CVOT trial results: https: nej.md 4qd5rLx New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS CVOT) NEJM Med Journal Club Diabetes Dialogue: Tirzepatide and SURPASS CVOT Topline Results HCPLive tirzepatide cardiovascular outcomes trial results july 2025 Demonstrates Cardioprotective Effects in SURPASS CVOT Breaking News: Real World Data What do topline data from SURPASS CVOT tell us about the potential of tirzepatide? , Check out the latest #DiabetesDialogue to hear from @DIanaMIsaacs and @Natalie_Bellini about the

Store: www.ab-travaux.com · Domain: www.ab-travaux.com